Skip to content
Brand AI

Celltrion

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    South Korean regulator fines three Celltrion companies

    Fine or penalty

    South Korea's Financial Services Commission fined Celltrion, Celltrion Healthcare and Celltrion Pharm a combined 13 billion won for accounting-rule violations. The regulator concluded the violations were unintentional.

    Source excerpt

    • On Friday, the FSC concluded that the three firms had violated accounting rules but it was "unintentional," an outcome that barely saved them from the possibility of stock trading suspension.
    • South Korea's financial regulator said Wednesday that it has fined three companies of pharmaceutical giant Celltrion a combined 13 billion won (US$10.5 million) for violating accounting rules.
    Source